$ENTB's Zander Therapeutics, Inc. (a wholly owned subsidiary of the Company) was granted a worldwide license to develop and commercialize certain of Regen BioPharma's cancer therapeutics (currently in development by Regen) for veterinary applications. David Koos, who is the CEO of the Company, also serves as CEO of Regen Biopharma, Inc.